Hemorrhoids
Drug research and approvals for hemorrhoids: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 37 studies of hemorrhoids are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 37
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Ligasure Versus Conventional Diathermy in HemorrhoidectomyNCT07878546 · Not applicable · Sohag University · starts Sep 25, 2026
- The Use of Electronic Bidets Compared to Water Rinsing After Surgery for Anal Fistula or Haemorrhoidal Disease: a Pilot…NCT07874711 · Not applicable · Universitair Ziekenhuis Brussel · starts Oct 1, 2026
- Sutureless Hemorrhoidectomy Versus Conventional Ligation in Advanced HemorrhoidsNCT07824999 · Not applicable · Sohag University · starts Oct 1, 2026
- AI-Assisted Written Information in Symptomatic Hemorrhoidal DiseaseNCT07701798 · Not applicable · Sanliurfa Education and Research Hospital · starts Jul 15, 2026
- Reproducibility of a Minimally Invasive Ferguson-type Hemorrhoidectomy for Grade III HemorrhoidsNCT07695649 · Not reported · Hospital Son Llatzer · starts Jun 15, 2026
- Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) in Patients With Haemorrhoids…NCT07647172 · Not reported · Servier Russia · starts Jun 30, 2026
- Prospective HemorrhoIdaL EmboliSation (PILES) RegistryNCT07635784 · Not reported · Joint & Vascular Institute · starts Jan 18, 2026
- SHAPE Versus Milligan-Morgan Hemorrhoidectomy for Hemorrhoidal DiseaseNCT07598630 · Not applicable · Cairo University · starts May 24, 2026
- Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSNCT07559630 · Not applicable · Jessica K. Stewart, MD · starts May 19, 2026
Approved 19
- LidocaineSodium channel alpha subunit blocker
- Zinc oxideSunscreen/skin protectant
- DiltiazemVoltage-gated L-type calcium channel blocker
- FluocinonideGlucocorticoid receptor agonist
- NitroglycerinSoluble guanylate cyclase activator
- DibucaineSodium channel protein type V alpha subunit blocker
- TriamcinoloneGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Fluocinolone acetonideGlucocorticoid receptor agonist
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- PhenylephrineAdrenergic receptor alpha-1 agonist
- Isosorbide dinitrateSoluble guanylate cyclase activator
- ProcaineSodium channel alpha subunit blocker
- TetracaineSodium channel alpha subunit blocker
- Pramoxine
- Benzocaine
- Glycerin
- Fluocortolone
- Witch hazel
Phase 3 5
- BupivacaineSodium channel protein type IV alpha subunit blocker
- MetronidazoleDNA inhibitor
- IferanserinSerotonin 2a (5-HT2a) receptor antagonist
- Water
- Oxethazaine
Phase 2 3
- Hydrocortisone acetateGlucocorticoid receptor agonist
- Polidocanol
- Tribenoside
Phase 1 or earlier 1
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
How its trials ended
180 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 48% met their primary endpoint, 9% missed it and 43% stopped early.
- Completed, result not reported8145%
- Status unknown4123%
- Ongoing3519%
- Met its primary endpoint116%
- Stopped: other or unclear53%
- Stopped: enrollment or feasibility32%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA